RecruitingNCT05024175
Long-term Follow-up of Subjects Treated With CAR T Cells
Sponsor
Marcela V. Maus, M.D.,Ph.D.
Enrollment
45 participants
Start Date
Aug 7, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Subjects will be asked to participate leading up to the last DF/HCC corresponding main study visit.
- Subjects meeting the following criteria are eligible for study participation:
- Provision of voluntary written informed consent by subject
- CAR T cells were administered in DF/HCC IRB corresponding main study
Exclusion Criteria2
- Subjects meeting the following criterion are to be excluded from study participation:
- \- Subject unable to comply with study requirements
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTDisease assessments
CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol
PROCEDURETumor Biopsy
Tumor Biopsy per protocol
DIAGNOSTIC_TESTBlood test
Blood Test per protocol
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05024175
Related Trials
A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma
NCT076786841 location
The Effects of Endotracheal Suctioning on Pain and Serum Markers
NCT066924001 location
Hydroponic vs Conventional Spinach Smoothies: Effects on Salivary Nitrate Bioavailability and Blood Pressure
NCT076659441 location
Study of New Magnetic Resonance Imaging Methods of the Brain
NCT000045771 location
Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity
NCT075879441 location